Latest Press Releases View all May 06, 2026 Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany May 04, 2026 Vertex Reports First Quarter 2026 Financial Results Apr 06, 2026 Vertex to Announce First Quarter 2026 Financial Results on May 4th View all Featured Media Library Items View all Reshma Kewalramani, M.D. Chief Executive Officer and President Download Duncan McKechnie Executive Vice President and Chief Commercial Officer Download Vertex International Headquarters – Lobby Download View all
May 06, 2026 Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany